FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer

Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60% of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40% of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Hui-Wen, Chang, Jeng-Shou, Lin, Hui-Yu, Lee, Hsun-Hua, Kuei, Chia-Hao, Lin, Che-Hsuan, Huang, Huei-Mei, Lin, Yuan-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209951/
https://www.ncbi.nlm.nih.gov/pubmed/30301218
http://dx.doi.org/10.3390/jcm7100330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209951/
https://www.ncbi.nlm.nih.gov/pubmed/30301218
http://dx.doi.org/10.3390/jcm7100330

Ejemplares similares